Goodyear Tire & Rubber Co vs Viatris Inc — how do they compare? Goodyear Tire & Rubber Co trades at $5.96 (market cap $1.75B), while Viatris Inc trades at $16.3 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 10.7× Goodyear Tire & Rubber Co's market cap, and Viatris Inc pays a 2.95% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals.
| GT | VTRS | |
|---|---|---|
Market Cap | $1.75B | $18.69B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $17.86 |
52-Week Low | $5.58 | $9.49 |
Enterprise Value | $9.11B | $30.80B |
Dividend Yield | — | 2.95% |
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $5.955, down 1.24% on the day, with a bearish technical signal and mixed analyst sentiment. The company reported a Q2 2026 loss of $0.61 per share, beating expectations but reflecting ongoing volume pressure. Revenue trends show a decline from $20.8B in 2022 to $17.7B projected for 2026, with negative net income margins. Valuation metrics appear attractive with P/E of 4.69 and P/B of 0.62, but profitability remains challenged with ROE at -63.93%.
The outlook remains cautious as Goodyear faces persistent volume declines and competitive pressures, though cash flow improvements and Asia Pacific gains provide some support. Investment opportunity exists in the deeply discounted valuation if operational turnaround succeeds, but risks include continued market share erosion and high debt levels. Analyst consensus shows 34.6% buy ratings with 50% recommending hold, indicating Wall Street's wait-and-see approach.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Trailing returns across standard periods
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →